Sarepta insider reports PSU vesting and tax share cuts

Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity. On March 1, 2026, 8,125 Performance Stock Units previously earned under a March 1, 2024 PSU award vested and were converted into the same number of common shares, based on the compensation committee’s milestone achievement determination. On March 2, 2026, the company withheld 3,718 and 767 common shares, respectively, at $16.20 per share to cover tax withholding obligations related to the vesting of PSU and RSU awards, leaving Rodino-Klapac with 227,670 directly held common shares.

Insider Trade Summary

8,125 shares exercised/converted

Exercise 4 txns

Insider Rodino-Klapac Louise

Role President, R&D and Tech Ops

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,718	$16.20	$60K
Exercise Price or Tax Liability	Common Stock	767	$16.20	$12K
Exercise	Performance Stock Units	8,125	$0.00	$0.00
Exercise	Common Stock	8,125	$0.00	$0.00

Holdings After Transaction: Performance Stock Units — 0 contracts (Direct); Common Stock — 227,670 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.
2. F2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.
3. F3. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Sarepta Therapeutics (SRPT) report for Louise Rodino-Klapac?

Sarepta reported that Louise Rodino-Klapac had 8,125 Performance Stock Units vest and convert into common stock, and then had 3,718 and 767 shares withheld by the company to cover tax obligations linked to PSU and RSU vesting events.

Were the Sarepta (SRPT) Form 4 transactions open-market stock sales?

No, the Form 4 for Sarepta shows tax-withholding dispositions, not open-market sales. Shares were withheld by the company at $16.20 per share solely to satisfy tax obligations arising from the vesting of previously granted performance stock units and restricted stock units.

How many Sarepta (SRPT) shares did Louise Rodino-Klapac acquire through PSU vesting?

Louise Rodino-Klapac acquired 8,125 common shares through the vesting and conversion of a Performance Stock Unit award. These PSUs were earned under a March 1, 2024 grant after the compensation committee determined that Sarepta met the specified performance milestones.

What were the tax-withholding share amounts in the Sarepta (SRPT) Form 4?

The Form 4 shows two tax-withholding dispositions: 3,718 common shares and 767 common shares, both at $16.20 per share. These shares were withheld by Sarepta to cover tax obligations from the vesting of performance stock units and restricted stock units granted in 2024.

What is Louise Rodino-Klapac’s reported Sarepta (SRPT) share ownership after these transactions?

After the reported vesting and tax-withholding events, Louise Rodino-Klapac directly holds 227,670 Sarepta common shares. This figure reflects the net position following the conversion of 8,125 Performance Stock Units and the subsequent share withholdings for tax obligations.

What performance conditions were tied to the vested Sarepta (SRPT) PSU award?

The vested PSU award was granted on March 1, 2024 and earned based on Sarepta’s achievement of specified milestones. The compensation committee determined that the company met these prescribed milestones, resulting in 8,125 shares vesting and converting into common stock on March 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		M		8,125	A	(1)	232,155	D
Common Stock	03/02/2026		F(2)		3,718	D	$16.2	228,437	D
Common Stock	03/02/2026		F(3)		767	D	$16.2	227,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	03/01/2026		M			8,125	(1)	(1)	Common Stock	8,125	$0	0	D

Explanation of Responses:

1. Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.

3. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.